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Abstract
Background: Answering questions such as “Which genes are related to breast cancer?” usually requires retrieving
relevant publications through the PubMed search engine, reading these publications, and creating gene lists. This
process is not only time-consuming, but also prone to errors.
Results: We report GLAD4U (Gene List Automatically Derived For You), a new, free web-based gene retrieval and
prioritization tool. GLAD4U takes advantage of existing resources of the NCBI to ensure computational efficiency.
The quality of gene lists created by GLAD4U for three Gene Ontology (GO) terms and three disease terms was
assessed using corresponding “gold standard” lists curated in public databases. For all queries, GLAD4U gene lists
showed very high recall but low precision, leading to low F-measure. As a comparison, EBIMed’s recall was
consistently lower than GLAD4U, but its precision was higher. To present the most relevant genes at the top of a
list, we studied two prioritization methods based on publication count and the hypergeometric test, and
compared the ranked lists and those generated by EBIMed to the gold standards. Both GLAD4U methods
outperformed EBIMed for all queries based on a variety of quality metrics. Moreover, the hypergeometric method
allowed for a better performance by thresholding genes with low scores. In addition, manual examination suggests
that many false-positives could be explained by the incompleteness of the gold standards. The GLAD4U user
interface accepts any valid queries for PubMed, and its output page displays the ranked gene list and information
associated with each gene, chronologically-ordered supporting publications, along with a summary of the run and
links for file export and functional enrichment and protein interaction network analysis.
Conclusions: GLAD4U has a high overall recall. Although precision is generally low, the prioritization methods
successfully rank truly relevant genes at the top of the lists to facilitate efficient browsing. GLAD4U is simple to use,
and its interface can be found at: http://bioinfo.vanderbilt.edu/glad4u.
Background
The physical development and phenotype of organisms
can be thought of as a product of genes interacting with
each other and with the environment. Therefore, it is
common for a scientist to ask questions like “Which
genes are related to breast cancer?”, “Which genes are
involved in embryonic development?”, and “Which genes
are functionally related to TP53?”
The current answers to these questions are primarily
contained in the articles indexed in the MEDLINE data-
base. Traditionally, answering these questions requires
individuals to retrieve relevant publications through the
PubMed search engine and then to create gene lists by
manually extracting gene-centered information from
retrieved literature. This process is not only time-consum-
ing, but also prone to errors. First, it is difficult to ascertain
that all relevant literature is processed. Second, it is unli-
kely that all relationships in a publication will be detected.
Third, individual researchers tend to extrapolate based on
domain knowledge.
* Correspondence: bing.zhang@vanderbilt.edu
1Department of Biomedical Informatics, Vanderbilt University School of
Medicine, 400 Eskind Biomedical Library, 2209 Garland Avenue, Nashville, TN
37232, USA
Full list of author information is available at the end of the article
Jourquin et al. BMC Genomics 2012, 13(Suppl 8):S20
http://www.biomedcentral.com/1471-2164/13/S8/S20
© 2012 Jourquin et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Over the past decade, bioinformatics approaches have
been developed to address this issue. One of the most suc-
cessful projects in this area is the Gene Ontology (GO)
project [1]. GO produces a structured, precisely defined,
and controlled vocabulary (i.e., GO terms) for describing
the roles of genes and gene products in different species.
Genes are associated with GO terms through manual
curation as well as computational inference. A researcher
can now go to the GO website [2] to get a list of genes
related to a GO term of interest. However, as the GO
vocabulary only describes gene products in terms of their
associated biological processes, cellular components and
molecular functions, users are limited by questions linked
to this limited vocabulary. Moreover, processes, functions
or components that are unique to diseases, such as onco-
genesis, are not included in GO because causing cancer is
not the normal function of any gene.
A useful resource specifically designed for disease stu-
dies is the Online Mendelian Inheritance in Man (OMIM
[3]) project. OMIM is a comprehensive, authoritative,
and timely compendium of human genes and genetic
phenotypes. It contains information on all known Men-
delian disorders. However, information on complex dis-
eases such as cancer and diabetes is lacking in OMIM.
In addition to manual curation, text mining tools have
been developed to assist gene list creation [4]. As an
example, EBIMed [5,6] combines text mining with co-
occurrence-based analysis to generate a prioritized list of
genes for a user-provided query. Specifically, EBIMed
collects MEDLINE records and available full text docu-
ments for a user-provided query, identifies protein
names, drugs, species, or GO terms in the documents,
and prioritizes genes/proteins based on the number of
co-occurrences of the different pairs (protein/protein,
protein/drug, protein/species, protein/GO term) in the
sentences of the documents in which they appear.
EBIMed and similar tools, such as FACTA [7] and SciMi-
ner [8], provide more flexible ways to create gene lists
that are not limited to certain aspects of biology. Never-
theless, they usually require heavy computation, and the
relevance of the resulted gene lists to the input queries
has not been systematically evaluated.
Here, we report GLAD4U (Gene List Automatically
Derived For You), a new web-based gene retrieval and
prioritization tool. GLAD4U takes advantage of existing
resources at the National Center for Biotechnology Infor-
mation (NCBI) to ensure computational efficiency. It
provides a simple user interface that facilitates intuitive
usage and interpretation of results. The quality of gene
lists created by GLAD4U is assessed using corresponding
“gold standard” lists curated in GO, GAD (Genetic Asso-
ciation Database [9]), and OMIM. The performance of
GLAD4U is also compared with EBIMed.
Results
Overall quality of the retrieved gene lists
GLAD4U relies on the NCBI eSearch API to find publi-
cations related to a user query and on the gene-to-publi-
cation link table to identify genes from the retrieved
publications. We used three GO biological process terms
(apoptosis, cell adhesion and DNA repair) and three dis-
ease terms (hypertension, obesity and schizophrenia) as
queries to evaluate the overall quality of the retrieved
gene lists. For each query, using a corresponding gene list
curated by GO or GAD/OMIM as a gold standard, we
calculated the precision, recall and F-measure of the
retrieved gene list. As shown in Table 1, gene lists
retrieved for all queries showed very high recall (0.90
±0.03 for GO terms and 0.96±0.05 for disease terms). In
contrast to the high recall, the precision was generally
low (0.16±0.04 for GO terms and 0.06±0.02 for disease
terms), leading to low F-measures (0.27±0.05 for GO
terms and 0.12±0.03 for disease terms). EBIMed’s recall
is consistently lower than GLAD4U (0.47±0.15 for GO
terms and 0.44±0.11 for disease terms). However, its pre-
cision is higher than GLAD4U (0.20±0.05 for GO terms
and 0.16±0.04 for disease terms), resulting in better
F-measures (0.27±0.03 for GO terms and 0.23±0.04 for
disease terms).
The low precision of GLAD4U may be partially attrib-
uted to the incompleteness of the annotation in GO and
GAD/OMIM. However, it is likely that the original gene
lists include many irrelevant genes. In this case, a priori-
tization step that ranks truly relevant genes at the top
of a list would certainly facilitate efficient browsing.
Performance of the prioritization methods
We studied the performance of two methods to prioritize
the gene lists. The first, “GLAD4U Counts”, is based solely
on the number of supporting publications as commonly
implemented in other software [10,11]. The second,
“GLAD4U Hypergeometric”, is proposed in this study,
which is based on the Hypergeometric test (see the Meth-
ods section for details). We used the above mentioned
three GO terms and three disease terms as queries to eval-
uate the performance of our prioritization methods. We
also included the prioritized gene lists returned by
EBIMed for comparison.
Figure 1 depicts the precision/recall curves from this
comparative evaluation. For all queries, based on manual
inspection of the curves, both GLAD4U Counts and
GLAD4U Hypergeometric outperformed EBIMed, espe-
cially at the high precision range. Between the two
GLAD4U methods, the Hypergeometric method per-
formed better than the Counts method for GO term
queries, while their performances were comparable for
disease term queries. The superior overall performance
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of the two GLAD4U methods over EBIMed was further
evaluated by computing AP, a quantitative measure of
quality across all recall levels (Table 2). In this analysis,
GLAD4U Counts and Hypergeometric methods scored
better than EBIMed (0.48±0.10, 0.52±0.12 and 0.21±0.09,
respectively), with GLAD4U Hypergeometric performing
the best (Table 2).
The precision-recall curve and the AP score factor in
precision at all recall levels. For ranked gene lists, parti-
cularly in web-based applications, this may not be of
interest to users. In most scenarios, what matters may
be the number of relevant genes on the first page or the
first several pages. “Precision at k“ is usually used to
measure precision at a fixed low level of retrieved
results, e.g., the top k results. To this end, we calculated
the precisions for the top 50 (k = 50) and top 100 (k =
100) genes for all three methods, for each query (Table
2). GLAD4U Counts and GLAD4U Hypergeometric
methods maintained higher precisions for the top 50
genes compared to EBIMed (0.74±0.15, 0.77±0.20 and
0.54±0.18, respectively), as well as for the top 100 genes
(0.64±0.20, 0.69±0.25 and 0.42±0.20, respectively).
Although the AP-based comparison may be biased
against EBIMed owing to its low overall recall, precision
at 50 and 100 only focus on the top ranking genes and
are not affected by the overall recall. These results sug-
gest that GLAD4U can produce lists where relevant
genes are ranked at the top.
Although precision was less than perfect even for the
top ranking genes, we noticed that many false-positives
could be explained by the incompleteness of the gold
standards. Table 3 lists the first 10 genes–along with
their first 10 supporting publications–returned by
GLAD4U Hypergeometric method that were not in the
corresponding gold standards for the terms “apoptosis”
and “hypertension” (see additional files 1 and 2 for the
complete lists of genes and supporting publications).
Taking the first and last genes in the list as examples,
for each term (i.e., MDM2 and ING1 for apoptosis, and
REN and ACE2 for hypertension), we found strong evi-
dence in the most recent supporting publications for
linking these non-gold standard genes to the query.
MDM2 has antiapoptotic effects, and its direct interac-
tion and regulation of p53 define it as an oncogene
[12-15]. It translocates to the nucleus to interact with
p53 and p300, promotes cell growth by initiating p53
degradation [16,17]. Its expression is directly linked to
prostate cancer patient susceptibility [18]. Inhibitor of
growth family, member 1 (ING1) is involved in cell
stress and DNA damage response [19-22]. Up-regulation
of p33ING1b or p24ING1c, two of the three alterna-
tively spliced transcripts of ING1 resulted in increased
early apoptotic cells [23,24], probably through interac-
tions with mdm2, p14arf, and lamin A [25,26]. This
effect is dependent on the presence of functional p53
[25,27] and the H3K3me3 binding domain of IGN1 [28].
Table 1 Overall quality of the retrieved gene lists
Query GO/ MIM gene count GLAD4U gene count EBIMed gene count GLAD4U EBIMed
Apoptosis 1039 6037 (958) 1469 (387) Precision 0.1587 0.2634
[195715] [10000] Recall 0.9220 0.3725
F-measure 0.2708 0.3086
Cell adhesion 785 4195 (691) 1725 (305) Precision 0.1647 0.1769
[125144] [10000] Recall 0.8802 0.3885
F-measure 0.2775 0.2431
DNA repair 282 2476 (263) 1100 (180) Precision 0.1062 0.1636
[60952] [10000] Recall 0.9326 0.6383
F-measure 0.1907 0.2605
Hypertension 87 2046 (77) 135 (27) Precision 0.0376 0.2000
[323818] [10000] Recall 0.8851 0.3103
F-measure 0.0721 0.2432
Obesity 111 1778 (110) 350 (59) Precision 0.0619 0.1686
[141615] [10000] Recall 0.9910 0.5315
F-measure 0.1165 0.2560
Schizophrenia 94 1725 (90) 382 (44) Precision 0.0522 0.1152
[91194] [10000] Recall 0.9574 0.4681
F-measure 0.0990 0.1849
Numbers in parentheses indicate the number of genes overlapping between the GLAD4U or EBIMed lists and the corresponding gold standard, numbers in
square brackets indicate the number of publications retrieved by the query.
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Regarding hypertension, renin (REN) is part of the
renin-angiotensin system (RAS). Proteins in this system
are thought as important regulators of blood pressure
and are involved in the onset of hypertension [29-32].
Figure 1 Precision/recall curves for different prioritization methods. Precision/recall curves for GLAD4U Counts, GLAD4U Hypergeometric
and EBIMed are colored in black, red, and green, respectively. Dashed lines correspond to the precision levels of 0.8 and 0.5.
Table 2 Comparison of different prioritization methods
Apoptosis Cell Adhesion DNA Repair Hypertension Obesity Schizophrenia
GLAD4U Counts
AP 0.4939 0.4611 0.6670 0.3947 0.5698 0.4601
Precision at k = 50 0.8600 0.8000 0.8800 0.4800 0.7800 0.5400
Precision at k = 100 0.8300 0.7300 0.8100 0.3800 0.5500 0.4200
GLAD4U Hypergeometric
AP 0.4942 0.5723 0.8139 0.4564 0.4782 0.4280
Precision at k = 50 0.9400 0.9000 1.0000 0.5800 0.6200 0.4800
Precision at k = 100 0.9000 0.8500 0.9700 0.3900 0.5200 0.4400
EBIMed
AP 0.1567 0.1256 0.3517 0.1336 0.2673 0.2318
Precision at k = 50 0.6200 0.4800 0.8400 0.3137 0.5652 0.4423
Precision at k = 100 0.5980 0.4848 0.6700 0.2821 0.1586 0.3200
AP: Average Precision
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Overexpression of REN leads to hypertension via
chronic overproduction of AngII [33,34], and inhibiting
the regulators of the RAS–such as REN–is a common
treatment for hypertension [32]. Adiponectin (ADIPOQ)
is an adipocytokine synthesized by the adipose tissue. It
has been proposed as a biomarker for hypertension, as
low plasma levels correlates with higher risk of hyper-
tension [35-38], and possibly with coronary artery dis-
ease, kidney disease, left ventricular hypertrophy, and
even myocardial infarction [36,39-41]. Interestingly,
REN and ADIPOQ also present polymorphisms, which
seem linked to therapeutic response to hypertension
[31,40,42-46].
From these publications, we believe that MDM2 and
IGN1 should be part of the apoptosis list, as well as REN
and ADIPOQ should be part of the hypertension list.
These results accentuate the incompleteness of the gold
standards and suggest that GLAD4U can help in the
completion of the gold standard lists.
Thresholding score to enhance GLAD4U performance
To evaluate whether thresholding the gene score can
enhance GLAD4U performance, we acquired a broader
list of disease-associated gene lists curated by Kohler et al.
[47] and available from the GeneWanderer website
(http://compbio.charite.de/genewanderer). We extracted
32 “disease-gene families” to use as standards for evaluat-
ing GLAD4U performance before and after thresholding.
On average, GLAD4U performs 2.90-time better when
genes with low prioritization scores (i.e. prioritization
score < 2 or hypergeometric p value > 0.01) are removed,
as illustrated by comparing the F-measures (Figure 2). The
most increased performances were achieved for terms
such as “prostate cancer”, “obesity”, and “amyotrophic lat-
eral sclerosis” (folds of 7.28, 5.72, and 5.48, respectively)
(see additional file 3 for the before and after F-measures,
and corresponding fold-changes). The performances that
least benefited from thresholding the gene list included
“Noonan Syndrome, Costello syndrome, Cardiofaciocuta-
neous Syndrome”, “Nonsyndromic hearing loss”, and
“Chondrodysplasia punctata” (folds of 1, 1.16, and 1.17
respectively).
User interface
GLAD4U uses a simple query interface for users to submit
their queries. Any queries that are valid in a PubMed search
can be used in GLAD4U. In the query interface, users can
also modify the default parameters of the application,





41 4193 (MDM2) 53.5212 21051655, 21051533, 20849854, 20849851, 20832750, 20822933, 20708156, 20659896, 20657550, 20644561
48 1432 (MAPK14) 40.8288 20736797, 20573801, 20558744, 20473571, 20463961, 20430109, 20393480, 20345980, 20307495, 20299663
49 4609 (MYC) 37.27.98 20714214, 20598117, 20596624, 20573831, 20564213, 20515470, 20232342, 20071475, 19996270, 19966300
54 6774 (STAT3) 35.2695 20562100, 20514402, 20507639, 20490331, 20459702, 20447714, 20213502, 20197401, 20164027, 20154216
77 5580 (PRKCD) 23.3017 20548952, 20547768, 20471435, 20093486, 19932628, 19917613, 19875824, 19833733, 19808702, 19747914
78 29126 (CD274) 23.1218 20636820, 20617899, 20587542, 20506224, 20445553, 20363965, 19916867, 19826049, 19811426, 19794071
79 142 (PARP1) 22.9308 20940411, 20665026, 20644561, 20629644, 20564216, 20453000, 20388712, 20181890, 20177052, 20072652
86 406991 (MIR21) 18.9856 20813833, 20515755, 20514462, 20447717, 20404348, 20372781, 20371612, 20346171, 20153722, 20148895
96 7295 (TXN) 16.1886 20619274, 20430109, 20298786, 20103619, 19671194, 19566940, 19328186, 19120277, 18983687, 18848838
100 3621 (ING1) 15.3784 19085961, 18836436, 18801192, 18691180, 18655775, 18533182, 18388957, 17585055, 17379210, 16607280
Hypertension
10 5972 (REN) 61.9237 20925572, 20662730, 20577119, 20537141, 20429690, 20223792, 20160196, 19891555, 19673942, 19536175
12 3291 (HSD11B2) 45.7032 20597806, 19811365, 19150652, 18837962, 18573267, 18178212, 17551100, 16872738, 16778331, 16109323
14 4879 (NPPB) 36.9570 20713912, 20368210, 20350538, 20346360, 20234137, 20142024, 20113292, 20102554, 20087954, 20083731
17 4524 (MTHFR) 32.2080 21072525, 21060006, 20960113, 20852445, 20812180, 20717043, 20669348, 20637366, 20592457, 20479155
19 1401 (CRP) 31.9446 21044781, 20805569, 20733302, 20683147, 20676960, 20346360, 20339115, 20184533, 20074254, 20068351
20 4878 (NPPA) 31.6082 20577119, 20543198, 20368210, 20346360, 20137368, 19635983, 19479237, 19430483, 19346663, 19330901
21 155 (ADRB3) 28.4824 20831043, 20144152, 20044737, 19842096, 19779464, 19479237, 19131662, 18724972, 18510051, 18088254
24 1584 (CYP11B1) 24.8304 20708777, 20339375, 19820005, 19567537, 19082699, 18663314, 18294861, 17980006, 17296872, 17121536
27 59272 (ACE2) 21.4649 20831027, 20813695, 20679547, 20349406, 20160196, 20117991, 19926873, 19684612, 19289653, 19286756
29 9370 (ADIPOQ) 19.6898 21044781, 20593932, 20552610, 20528971, 20516205, 20443850, 20385503, 20376890, 20166815, 20150538
* Only the 10 most recent supporting publications are shown here. See additional files 1 and 2 for the complete list of false-positive genes and their
corresponding supporting publications.
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including: search space (all species or restricted to human
genes), the number of genes to present per result page, the
maximum number of publications supporting each gene
returned in the result page and the number of pages to
build for each of the algorithm runs.
The output page displays the ranked gene list and infor-
mation associated with each gene (Figure 3). As each gene
is identified by an Entrez-Gene ID, we use eSummary,
another NCBI’s eUtility [48], to fetch annotations for the
gene including name, symbol and species. Publications sup-
porting the relationship between a gene and the query term
are listed under the gene. The publications are ordered
based on their PubMed IDs so that the most recent publi-
cation is listed first (see Figure 3, under the “ADIPOQ”
gene description). As for genes, we use eSummary to fetch
information for the publication such as title, author and
journal name. Genes and publications are hyperlinked to
the corresponding NCBI pages, which will–by design–open
in a new window to avoid disrupting the result page.
At the top of the output page, a summary of the run is
also given: query term and options chosen, number of
genes and publications processed, as well as a hyperlink to
download the complete results in the comma-separated
values (CSV) format. Although this file may be difficult to
interpret by humans, it can be used as input for other
computational analysis tools. For example, we have imple-
mented a “send data to Functional Enrichment Analysis”
link in the result page (Figure 3) of GLAD4U for submit-
ting a gene list to the functional enrichment analysis tool
WebGestalt [49,50]. This function is particularly handy for
the functional interpretation of a gene list, e.g., a list
returned by a disease term query. It could help revealing
biological processes associated with the disease. As an
example, enrichment analysis on the first 100 genes
returned by the “Obesity” query linked this disease to bio-
logical processes such as “fat cell differentiation” (20
genes, multiple-test adjusted enrichment p-value (adjp) =
5.27e-28), “lipid metabolic process” (39 genes, adjp =
5.05e-20) and “response to insulin stimulus” (17 genes,
adjp = 4.99e-18). In addition, we have also implemented a
“visualize genes in a protein-protein interaction network”
link, which allows the visualization of interactions among
the protein products of the genes based on the Cytoscape
Web utility (http://cytoscapeweb.cytoscape.org/).
Figure 2 F-measure evaluations of GLAD4U before and after thresholding. F-measure evaluations of GLAD4U before and after thresholding,
for each disease-associated gene lists. A higher F-measure indicates a better GLAD4U performance.
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Figure 3 GLAD4U output page. A typical result page generated by a query with GLAD4U. The summary section presents the main statistics for
the query, along with two hyperlinked icons to download the results as an entire archive of all pages of results ("compressed” icon), a CSV
("Excel” icon) or a text ("text” icon) file. Right below the summary, a link is available to send the results for functional enrichment analysis. In the
main result section, the prioritized genes are presented. The user can click the “+” to show/hide the supporting publications, which are all
hidden by default to help the read-out of the gene information. ADIPOQ gene is presented with its supporting publications as an example.
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Discussion
Reading through all relevant literature to generate a gene
list is time consuming [10,51-53], a common concern
that came up in all interviews of experimentalists that we
performed (results not shown). GLAD4U addresses this
problem by automatically creating a ranked list of genes
following a user’s input query.
One important feature of GLAD4U is its information
processing. Based on our survey among experimentalists,
GLAD4U follows the exact same steps that an experi-
mentalist would follow: gather literature, extract gene
information and create an expert list [54]. Whether a
user queries a disease, a non-disease phenotype, a biolo-
gical process or a gene, GLAD4U will fetch correspond-
ing biomedical publications using NCBI’s eUtilities API,
retrieve relevant gene information, rank them and send
them back to the user. GLAD4U ensures computational
efficiency through effective use of existing NCBI
resources, which also made it one of the winning applica-
tions in the National Library of Medicine (NLM)’s 2011
Software Development Challenge on the Innovative Uses
of NLM Information.
Another important feature of GLAD4U is its simplicity.
Researchers will be at ease using GLAD4U because its
searching engine is powered by PubMed’s API [48,52],
and behaves similarly to Entrez-PubMed [55]. GLAD4U
outputs a clean result page where the user can easily find
genes relevant to the concept queried and supporting
publications. Additionally, the use of PubMed’s API
makes GLAD4U almost maintenance-free. GLAD4U will
update itself along with the MEDLINE library update.
This will ensure that GLAD4U’s results will always be
up-to-date with the current literature.
Several tools rely on PubMed to build disease candidate
genes lists [5,8,52,56,57]. EBIMed [5] and FACTA [7] are
concept-oriented applications for mining existing biome-
dical literature. They attempt to automatically establish
the publication-concept (including genes) relationship
through in-house text mining tools whereas GLAD4U
relies on the manually curated publication-gene mapping
provided by NCBI. According to our results, manual
mapping seems to have notable impact on performance.
Nevertheless, automated mapping would allow flexibility
in extending the services for concepts other than genes.
Although using the biomedical literature as a knowl-
edge source seems intuitive [51,58,59], certain limitations
exist: the literature is indexed based on titles, abstracts
and keywords, not on full-text [60,61]. Thus, a set of pub-
lications retrieved may be incomplete (i.e., some publica-
tions relevant to the concept queried will not be retrieved
because they do not contain the necessary keywords in
their titles or abstracts) [62]. There is a possible bias in
using the biomedical literature and ontology [55], as the
most studied genes (those with the most publications)
will have more weight [51,63] at the expense of more
relevant genes that might only be featured in few papers
[64]. Thus, we use the hypergeometric test to rank genes
based on how likely it would be to retrieve them by
chance alone, based on the number of publications
retrieved for this gene among the total number of publi-
cations linked to this gene. The less likely it is–the smal-
ler the p value–the higher the score will be for the gene.
Thus, even if GLAD4U is solely retrieving its data from
the biomedical literature, it prioritizes following a statisti-
cal analysis of the retrieved data.
The most obvious usage of GLAD4U is to generate a
gene list for an input concept, which has been demon-
strated in this paper. This can be extremely useful for the
design of targeted high-throughput experiments. If one
needs to create a custom array or selected proteins for
targeted quantitative proteomic analysis using the
selected reaction monitoring (SRM) assay, one can use
GLAD4U and review the ranked list of genes that likely
should be included in the experimental design. Besides
generating gene lists for individual concepts, GLAD4U is
very flexible and allows production of gene lists related
to multiple concepts, which cannot be done by searching
GO or OMIM databases. For example, a query of “smok-
ing AND cancer” can generate a gene list that could
potentially help exploring gene-environment interactions
in cancer. GLAD4U also holds the potential to assist in
improvement of the functional annotation of genes.
Although GO contains more than 17,000 terms [4,65]
and is regularly used in the bioinformatics field as a stan-
dard [4,66], it is not complete [51,67]. Through manual
checking of the top genes returned by GLAD4U that
were not part of the gold standard lists, we easily found
evidence that these genes were indeed linked to the
query, and probably should have been included in the
gold standard.
Finally, because GLAD4U prioritization algorithm
assigns scores to genes, removing the genes with a low
score consistantly improves the quality of the results. This
result justifies thresholding GLAD4U results by default.
Conclusions
GLAD4U is a freely available web-application for creating
expert candidate gene lists tailored to a user’s query. It fol-
lows the same steps that the experimentalist would follow:
gather literature, extract gene information and create an
expert list. The simple interface of GLAD4U ensures easy
usage and interpretation. Because GLAD4U relies on
existing biomedical literature, it has an immediate credibil-
ity with experimentalists, who use this resource as a pri-
mary means for enhancing their knowledge and expertise.
Although the gene list directly returned from a PubMed
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query is usually lengthy and noisy, the prioritization
method implemented in GLAD4U successfully ranks truly
relevant genes at the top of the list and facilitates efficient
browsing of the list.
Methods
Publication retrieval
GLAD4U relies on the eSearch application programming
interface (API) developed by the NCBI for retrieving pub-
lications from the MEDLINE database [48]. For a user
query, eSearch returns an XML file containing the num-
ber of publications returned by the query and all publica-
tion identification IDs (PMIDs). The XML file is parsed
to get the list of PMIDs associated with a user query.
Gene retrieval
Genes associated with PMIDs are retrieved based on the
gene-to-publication link table provided by Entrez-Gene
[68]. Links between Entrez-Gene IDs and PMIDs are cre-
ated based on both manual curation within the NCBI
and integration of information from other public data-
bases. Publications linked to more than 500 genes are
removed from the link table because they lack specificity.
After this process, the link table included 3,509,732 genes
and 647,523 publications for all organisms, among which
30,343 genes and 306,487 publications were related to
human (as of 05/14/2011).
Gene prioritization
We studied two methods to prioritize the retrieved genes
based on publication counts or the hypergeometric test.
To prioritize using counts ("GLAD4U Counts”), each
gene receives a score equal to the number of publications
describing it in the link table. The other method
("GLAD4U Hypergeometric”) uses the hypergeometric
test to prioritize all retrieved genes. Specifically, for a
given query Q and a gene G, let n be the number of pub-
lications retrieved for the query and present in the gene-
to-publication link table (query-relevant publications)
and k be the number of query-relevant publications that
involves the gene G. Let us further assume that there are
m publications in the gene-to-publication link table, j of
which involve the gene G (gene-relevant publications).
This method calculates the probability of observing k or
more query-relevant publications for the gene by chance,
based on the hypergeometric test and scores the gene
using the following formula:
















We used GO and disease terms as queries to evaluate
the performance of the GLAD4U algorithms. Gene
lists curated in GO, OMIM and GAD [69] were used
as a gold standard (i.e. relevant genes). We developed
a Perl script to parse the files “gene2go.gz” [68] and
“gene_ontology.1_2.obo” [70] in order to generate gene
lists for GO terms (as of 12/20/2009). Because of the
parent-child relationship among the GO terms as
described in the GO Direct Acyclic Graph, genes with
granular annotations were associated with their parent
terms using the Perl script. Using GAD, we identified
all genes associated to a disease term. Using OMIM,
we retrieved all IDs prefixed with “%” and “#” with the
query in the title. Corresponding gene IDs were
mapped by parsing the file “mim2gene” [68] (as of 12/
22/2009). For each disease term, the lists obtained with
GAD and OMIM were merged to serve as a gold stan-
dard. Retrieval performance was evaluated using preci-
sion, recall and F-measure. The F-measure is calculated
by 2pr/(p+r), where p is the precision defined as∣∣{relevant genes} ∩ {retrieved genes}∣∣ / ∣∣{retrieved genes}∣∣ and r is the re-
call defined as
∣∣{relevant genes} ∩ {retrieved genes}∣∣ / ∣∣{relevant genes}∣∣.
We used the precision/recall curve, average precision
(AP) and precision at the top k retrieved genes (k = 50
and k = 100) to evaluate the performance of our gene
prioritization methods, and compared it to the perfor-
mance of the ranked lists generated by EBIMed [6].
All performance values are expressed in the text as
mean ± standard deviation.
Web implementation
The GLAD4U user interface was developed in HTML and
PHP languages. The scripts to deploy and update the algo-
rithm on web servers were written in Perl, while the gen-
eration of hypergeometric test scores is using C. JQuery
was used to implement user-features such as the ability to
hide/ show options and functions. An email notification
module was implemented to allow users to retrieve their
results at a later time. GLAD4U (http://bioinfo.vanderbilt.
edu/glad4u) is platform-independent and under a GNU
GPL license [71]. It was tested on Internet Explorer 5.0,
Firefox 3.0, Safari 3.0, Chrome, Netscape 7 or any higher
versions of these browsers.
Additional material
Additional file 1: False-positive genes retrieved by querying
“apoptosis” with GLAD4U. This table shows all genes retrieved by
GLAD4U with the query “apoptosis” that were not among the gold
standards. The table presents the rank and score of these genes and all
the retrieved supporting publications.
Additional file 2: False-positive genes retrieved by querying
“hypertension” with GLAD4U. This table shows all genes retrieved by
GLAD4U with the query “hypertension” that were not among the gold
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standards. The table presents the rank and score of these genes and all
the retrieved supporting publications.
Additional file 3: GLAD4U prioritization of disease candidate genes.
This table shows the number of genes associated with each
GeneWanderer hereditaty disease, retrieved by GLAD4U and overlapping
between the two lists before and after thresholding. F-measure fold
change between the GLAD4U prioritized list before and after
thresholding, as well as the actual F-measures are also displayed in the
table.
List of abbreviations used
ADIPOQ: adiponectin; API: application programming interface; CSV: comma-
separated values; GAD: genetic association database; GLAD4U Counts:
GLAD4U prioritization algorithm using counts; GLAD4U Hypergeometric:
GLAD4U prioritization algorithm using the hypergeometric test; GLAD4U:
gene list automatically derived for you; GO: gene ontology; GOTM: GOTree
Machine; ING1: inhibitor of growth family: member 1; AP: average precision;
NCBI: national center for biotechnology information; OMIM: online
mendelian inheritance in man; PMIDs: publication identification IDs; REN:
renin; SRM: selected reaction monitoring.
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